VytronUS Raises Funds, Loses CEO To New Abbott EP Biz
This article was originally published in The Gray Sheet
Executive Summary
The cardiac arrhythmia ablation device firm raised $31.6 million in a Series B financing, the same day its CEO was announced to be leaving for Abbott's new electrophysiology unit.
You may also be interested in...
Abbott Makes Three, Not Two, Investments In AFib Ablation
Abbott made a minority equity investment in VytronUS as part of the startup's latest funding round, according to the VytronUS' biggest institutional investor. That comes in addition to an acquisition and a right-to-purchase transaction for two other atrial fibrillation ablation firms, marking Abbott's entry into that market.
Abbott Enters Electrophysiology Fray With Topera, ACT Deals
The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.
Abbott Enters Electrophysiology Fray With Topera, ACT Deals
The diversified company is entering the atrial fibrillation catheter ablation for the first time. It is acquiring Afib ablation mapping system maker Topera and has gained rights to buy catheter developer Advanced Cardiac Therapeutics.